Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Completed · Phase 2 · Has a placebo group

Conditions studied: Hepatitis C Virus

In brief

To identify a shorter duration of antiviral therapy (12 or 16 weeks) for the combination of daclatasvir with pegylated interferon alfa-2a and ribavirin.

Key facts

Study ID: NCT01257204
Run by: Bristol-Myers Squibb
People needed: 196
Starts: 2010-12-01
Expected to finish: 2012-09-01
Last updated by the study team: 2015-12-14

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

California Liver Institute — Los Angeles, California, United States
Digestive Disease Associates, P.A. — Baltimore, Maryland, United States
Options Health Research, Llc — Tulsa, Oklahoma, United States
Alamo Medical Research — San Antonio, Texas, United States
Local Institution — Darlinghurst, New South Wales, Australia
Local Institution — Westmead Nsw, New South Wales, Australia
Local Institution — Adelaide, South Australia, Australia
Local Institution — Clayton Vic, Victoria, Australia
Local Institution — Fremantle, Western Australia, Australia
Local Institution — Camperdown, Australia
Local Institution — Calgary, Alberta, Canada
Local Institution — Edmonton, Alberta, Canada
Local Institution — Vancouver, British Columbia, Canada
Local Institution — Victoria, British Columbia, Canada
Local Institution — Winnipeg, Manitoba, Canada
Local Institution — Toronto, Ontario, Canada
Local Institution — Hvidovre, Denmark
Local Institution — Créteil, France
Local Institution — Lille, France
Local Institution — Montpellier, France
Local Institution — Nice, France
Local Institution — Paris, France
Local Institution — Pessac, France
Local Institution — Brescia, Italy
Local Institution — Cisanello (pisa), Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.